Samidorphan

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Samidorphan
Accession Number
DB12543
Description

Samidorphan has been used in trials studying the treatment of Schizophrenia, Alcohol Dependence, and Binge Eating Disorder.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 370.449
Monoisotopic: 370.189257325
Chemical Formula
C21H26N2O4
Synonyms
Not Available
External IDs
  • ALKS 33
  • ALKS-33
  • RDC-0313
  • RDC-0313-00

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AlfentanilThe therapeutic efficacy of Alfentanil can be decreased when used in combination with Samidorphan.
BenzhydrocodoneThe therapeutic efficacy of Benzhydrocodone can be decreased when used in combination with Samidorphan.
BuprenorphineThe therapeutic efficacy of Buprenorphine can be decreased when used in combination with Samidorphan.
ButorphanolThe therapeutic efficacy of Butorphanol can be decreased when used in combination with Samidorphan.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Samidorphan.
DextropropoxypheneThe therapeutic efficacy of Dextropropoxyphene can be decreased when used in combination with Samidorphan.
DezocineThe therapeutic efficacy of Dezocine can be decreased when used in combination with Samidorphan.
DiamorphineThe therapeutic efficacy of Diamorphine can be decreased when used in combination with Samidorphan.
DihydrocodeineThe therapeutic efficacy of Dihydrocodeine can be decreased when used in combination with Samidorphan.
DiphenoxylateThe therapeutic efficacy of Diphenoxylate can be decreased when used in combination with Samidorphan.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phenanthrenes and derivatives. These are polycyclic compounds containing a phenanthrene moiety, which is a tricyclic aromatic compound with three non-linearly fused benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenanthrenes and derivatives
Sub Class
Not Available
Direct Parent
Phenanthrenes and derivatives
Alternative Parents
Naphthalenecarboxamides / Benzazocines / Isoquinolones and derivatives / Tetralins / Salicylic acid and derivatives / 1-hydroxy-4-unsubstituted benzenoids / Aralkylamines / Piperidines / Vinylogous acids / Tertiary alcohols
show 10 more
Substituents
1,2-aminoalcohol / 1-hydroxy-4-unsubstituted benzenoid / 2-naphthalenecarboxamide / 2-naphthalenecarboxylic acid or derivatives / Alcohol / Amine / Amino acid or derivatives / Aralkylamine / Aromatic heteropolycyclic compound / Azacycle
show 25 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
7W2581Z5L8
CAS number
852626-89-2
InChI Key
RYIDHLJADOKWFM-MAODMQOUSA-N
InChI
InChI=1S/C21H26N2O4/c22-19(26)15-4-3-13-9-16-21(27)6-5-14(24)10-20(21,17(13)18(15)25)7-8-23(16)11-12-1-2-12/h3-4,12,16,25,27H,1-2,5-11H2,(H2,22,26)/t16-,20-,21-/m1/s1
IUPAC Name
(1R,9R,10S)-17-(cyclopropylmethyl)-3,10-dihydroxy-13-oxo-17-azatetracyclo[7.5.3.0^{1,10}.0^{2,7}]heptadeca-2(7),3,5-triene-4-carboxamide
SMILES
NC(=O)C1=C(O)C2=C(C[C@H]3N(CC4CC4)CC[C@@]22CC(=O)CC[C@@]32O)C=C1

References

General References
Not Available
PubChem Compound
11667832
PubChem Substance
347828769
ChemSpider
23259667
BindingDB
50165049
ChEMBL
CHEMBL426084
ZINC
ZINC000028478244
Wikipedia
Samidorphan

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentAlcohol Dependence1
2CompletedTreatmentAlcohol Use Disorder (AUD) / Schizophrenia1
2CompletedTreatmentBinge Eating Disorder (BED)1
2CompletedTreatmentSchizophrenia1
1CompletedNot AvailableCocaine Abuse1
1CompletedTreatmentAlcohol Dependence1
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentSubstance-Related Disorders1
1, 2CompletedNot AvailableMajor Depressive Disorder (MDD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.629 mg/mLALOGPS
logP1.09ALOGPS
logP0.46ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)7.88ChemAxon
pKa (Strongest Basic)8.94ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area103.86 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity101.04 m3·mol-1ChemAxon
Polarizability39.26 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 16:47 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates